ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

KVA K V Pharma CL A

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
K V Pharma CL A NYSE:KVA NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0 -

Law Offices of Howard G. Smith Announces Class Action Lawsuit Against K-V Pharmaceutical Company

03/11/2011 1:40am

Business Wire


K V Pharma CL A (NYSE:KVA)
Historical Stock Chart


From Dec 2019 to Dec 2024

Click Here for more K V Pharma CL A Charts.

Law Offices of Howard G. Smith, representing investors of K-V Pharmaceutical Company (“K-V" or the “Company”) (NYSE:KV-A) (NYSE:KV-B), has filed a class action lawsuit in the United States District Court for the Eastern District of Missouri on behalf of a class consisting of all persons or entities who purchased K-V securities between February 14, 2011 and April 4, 2011, inclusive (the “Class Period”).

K-V is a specialty pharmaceutical company engaged in the acquisition, development, manufacture and marketing of branded and generic/non-branded prescription pharmaceutical products in the United States, primarily focusing on women’s healthcare. The Complaint alleges that, during the Class Period, K-V and certain of the Company’s executive officers issued false and/or misleading statements concerning the Company’s business and financial prospects. Specifically, the Complaint alleges that defendants misrepresented that the Food and Drug Administration (FDA) had granted K-V the exclusive distribution rights over “Makena,” a drug used to prevent miscarriages, and that the FDA would enforce those rights by preventing K-V’s competitors from distributing generic formulations of the drug. The Complaint further alleges that defendants failed to disclosed that the drug’s $1,500 price actually would reduce the availability of Makena to low-income and other at-risk groups.

No class has yet been certified in the above action. Until a class is certified, you are not represented by counsel unless you retain one. If you purchased K-V securities between February 14, 2011 and April 4, 2011, you have until December 19, 2011, to move for lead plaintiff status. To be a member of the class you need not take action at this time; you may retain counsel of your choice or take no action and remain an absent class member. If you wish to discuss this action or have any questions concerning this Notice or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215)638-4847, Toll-Free at (888)638-4847, by email to howardsmith@howardsmithlaw.com or visit our website at http://www.howardsmithlaw.com.

1 Year K V Pharma CL A Chart

1 Year K V Pharma CL A Chart

1 Month K V Pharma CL A Chart

1 Month K V Pharma CL A Chart

Your Recent History

Delayed Upgrade Clock